New drugs in myelofibrosis: Critical assessment of additional value to monotherapy with JAK inhibitors

Naseema Gangat; Ayalew Tefferi

doi:10.1002/ajh.27248

New drugs in myelofibrosis: Critical assessment of additional value to monotherapy with JAK inhibitors

Hematology

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	978-981
Number of pages	4
Journal	American journal of hematology
Volume	99
Issue number	5
DOIs	https://doi.org/10.1002/ajh.27248
State	Published - May 2024

ASJC Scopus subject areas

Hematology

Access to Document

10.1002/ajh.27248

Cite this

@article{9bb783a238c941f4af98365f60abfc09,

title = "New drugs in myelofibrosis: Critical assessment of additional value to monotherapy with JAK inhibitors",

author = "Naseema Gangat and Ayalew Tefferi",

year = "2024",

month = may,

doi = "10.1002/ajh.27248",

language = "English (US)",

volume = "99",

pages = "978--981",

journal = "American journal of hematology",

issn = "0361-8609",

publisher = "Wiley-Liss Inc.",

number = "5",

}

TY - JOUR

T1 - New drugs in myelofibrosis

T2 - Critical assessment of additional value to monotherapy with JAK inhibitors

AU - Gangat, Naseema

AU - Tefferi, Ayalew

PY - 2024/5

Y1 - 2024/5

UR - http://www.scopus.com/inward/record.url?scp=85184904300&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85184904300&partnerID=8YFLogxK

U2 - 10.1002/ajh.27248

DO - 10.1002/ajh.27248

M3 - Letter

C2 - 38332640

AN - SCOPUS:85184904300

SN - 0361-8609

VL - 99

SP - 978

EP - 981

JO - American journal of hematology

JF - American journal of hematology

IS - 5

ER -

New drugs in myelofibrosis: Critical assessment of additional value to monotherapy with JAK inhibitors

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this